Updates in the Management of Early-Stage Diffuse Large B-Cell Lymphoma
Search for other papers by Thomas M. Habermann in
Current site
Google Scholar
PubMed
Several important updates have emerged in the management of early-stage diffuse large B-cell lymphoma. Three trials resulted in the approval of rituximab + cyclophosphamide/doxorubicin/vincristine/prednisone (R-CHOP) for use in these patients internationally. Furthermore, studies have been initiated to determine whether 4 or 6 cycles of this regimen should be administered without radiation therapy (RT). Six cycles of R-CHOP plus central nervous system (CNS) prophylaxis and prophylactic testicular RT are recommended for patients with extranodal disease occupying the testicles. Although controversial, there is a reasonable consensus in the literature to consider 6 cycles of R-CHOP plus involved-site RT and CNS prophylaxis for patients with extranodal disease of the breast. Patients with primary bone and gastric extranodal disease do not seem to derive a significant survival benefit from RT. Molecular subtype evaluations may change treatment approaches.
Disclosures: Dr. Habermann has disclosed serving as a consultant for Seagen, Tess Therapeutics, Lilly, MorphoSys, Incyte, BioGene, and Loxo Oncology.
© 2019-2023 National Comprehensive Cancer Network